Ureteral Stent Occlusion
Conditions
Brief summary
From June 2018 to October 2018, patients from two distinct clinical centers were prospectively enrolled in the study and stratified (non-randomly) into either control group A, patients who received polyurethane stents (Rüsch, Teleflex), or experimental group B, patients who received silicone stents (Cook Medical). Each participant completed a survey one hour after stent insertion, in the middle of the stent dwelling period, and before stent removal or ureteroscopy noting body pain and overactive bladder via the visual analog scale pain (VASP) and overactive bladder (OAB) awareness tool, respectively. Additionally, the successfulness of stent placement, hematuria, number of unplanned visits, and stent encrustation rates were assessed within each group.
Interventions
DEVICEpolyurethane stent
patients were prospectively enrolled in the study and stratified (non-randomly) into either group A - polyurethane - control group or group B - silicone - experimental group
DEVICEsilicone stent
silicone stent
Sponsors
St. Petersburg State Pavlov Medical University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Inclusion criteria included age (18 to 60 years old), * confirmed ureteral stone * prescribed ureteral stent placement for pain syndrome relief
Exclusion criteria
* an active urinary tract infection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| body pain | 4 weeks | At each follow-up appointment, patients completed a survey in which the visual analog scale pain (VASP) was filled |
| bladder overactivity | 4 weeks | At each follow-up appointment, patients completed a survey in which the bladder awareness tool (VASP) was filled |
Countries
Russia
Outcome results
None listed